(PharmaNewsWire.Com, May 17, 2019 ) According to research report the western blotting market is projected to reach USD 730.7 Million by 2021 from USD 574.8 Million in 2016, at a CAGR of 4.9% in the next five years (2016 to 2021). New product launches was the major growth strategy adopted by players in the western blotting market. The western blotting market is dominated by Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and GE Healthcare (U.S.). These players jointly accounted for approximately 80% of the market in 2016. Other players having significant presence in this market include Advasta, Inc. (U.S.), LI-COR Biosciences (U.S.), PerkinElmer, Inc. (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Cell Signaling Technology, Inc. (U.S.).). Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=235810711 Bio-Rad Laboratories, Inc. is the leading player in the western blotting market. The company is a leading manufacturer and supplier of products and systems to separate, detect, analyze, and purify complex biological and chemical materials. The company serves the fields of life science research, healthcare, and analytical chemistry with its innovative products and services. The company’s leading position in the market can be attributed to its wide customer base. Bio-Rad, with its 8,000 employees (as of 2015), serves a wide and diversified customer base that includes universities and research institutes, supporting about 150,000 scientists in the U.S.; companies operating in the pharmaceutical, biotechnology, chemical, and food industries; diagnostic manufacturers; and commercial laboratories and hospitals. Bio-Rad strategically focuses on company acquisitions and investments in companies with complementary technologies and product portfolios. For instance, in January 2013, Bio-Rad Laboratories acquired AbD Serotec (U.S.), a manufacturer of antibodies, kits, and accessories. Thermo Fisher Scientific, Inc. (U.S.) is another leading player in the western blotting market. A wide product portfolio, high focus on increasing company presence in the emerging economies, and continuous launch of new and innovative products are contributing to the company’s dominance in this market. The company’s products are made available through its broad sales force and a global network of resellers and distributors. The company has approximately 12,000 sales and service personnel, including highly trained technical specialists. The company has high focus on innovation through the launch of new products and acquisitions. During 2013 to 2016, the company made several acquisitions. For instance, in March 2016, Thermo Fisher acquired Affymetrix, Inc. (U.S.), a provider of innovative technologies that enable multiplex and parallel analysis of biological systems at the cell, protein, and gene levels. The acquisition was aimed at integrating Affymetrix’s major product groups into Thermo Fisher Scientific’s existing businesses. Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235810711 GE Healthcare is another major company in the western blotting market. GE Healthcare manufactures and supplies products and services in the fields of medical diagnostics, medical imaging and information technologies, drug discovery, and patient monitoring systems. Over the years, the company has launched various innovative and differentiated products. For instance, in September 2014, GE Healthcare launched Amersham WB system, a fully integrated fluorescence detection system, for western blotting and SDS-PAGE of proteins. In addition, in October 2013, GE Healthcare launched a new PVDF 0.2 ìm membrane, Amersham Hybond 0.2, specifically for chemiluminescence western blotting of smaller peptides and proteins. The introduction of such innovative products has helped the company to be a leading player in the western blotting market. The other players in this market have implemented various strategies to expand their global footprints and increase their market shares. Major growth strategies followed by market players include new product launches, agreements, collaborations, expansions, acquisitions, alliances, approvals, and partnerships. Product launches accounted for a major share followed by acquisitions, which accounted for the second-largest share of the total number of key growth strategies adopted by players in the western blotting market during 2013 to 2016. Expansions, agreements, collaborations, partnerships, product enhancement and market developments are some of the other strategies adopted by players to achieve growth in the western blotting market.
Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: 1-888-600-6441 newsletter@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
